Clinical Trials

Title   Chiltern Sotio SP005
Principal Investigator/ Physician   David Clarkson, MD
Protocol┬áNo.   SP005
Open Date   11/01/2014
Gender   Both
Cancer Site   Prostate
Status   Open
Sponsor   Sotio
Contact Email   MCI Clinical Trials
Summary  

Prostate Title:  "A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy."

Inclusion Criteria: Histologically or cytologically confirmed prostate adenocarcinoma; Presence of skeletal or soft-tissue/visceral/nodal metastasis; ECOG Performance status 0-2. Disease progression despite ADT as indicated by:  PSA increase that is ≥ 2 mg/mL and ≥ 25% above the minimum PSA as reached during ADT or above the pre-treatment level OR Progression of measurable lymph nodes (≥ 15mm) or visceral lesion measurable

Exclusion Criteria:  Confirmed brain and/or leptomeningeal metastases; Current symptomatic cord compression; Prior chemotherapy for prostate cancer; Treatment with anti-androgens, inhibitors of adrenal-produced androgens or other hormonal tumor-focused treatment performed on the day of screening or within previous four weeks

Clinical Trails.Gov Link: https://clinicaltrials.gov/ct2/show/NCT02111577?term=SP005&rank=1

Email Newsletters

Connect With Us